Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Diabetes and dyslipidaemia.

Sherwyn L Schwartz1

  • 1Diabetes and Glandular Disease Clinic, San Antonio, TX 78229-4801, USA.

Diabetes, Obesity & Metabolism
|June 17, 2006
PubMed
Summary
This summary is machine-generated.

Diabetic dyslipidaemia increases cardiovascular disease (CVD) risk. Managing it involves lifestyle changes, improved glycemic control, and lipid-lowering therapy when needed to reach target cholesterol levels.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma glucose and insulin response to two oral nutrition supplements in adults with type 2 diabetes mellitus.

BMJ open diabetes research & care·2016
Same author

A single-blind, placebo-controlled, dose-ranging trial of oral hepatic-directed vesicle insulin add-on to oral antidiabetic treatment in patients with type 2 diabetes mellitus.

Journal of diabetes science and technology·2014
Same author

Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studies.

Annals of medicine·2011
Same author

Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus.

Diabetes technology & therapeutics·2011
Same author

Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors.

The American journal of geriatric pharmacotherapy·2011
Same author

Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.

Expert review of medical devices·2010
Same journal

Exercise Resistance in Obese Male NZO Mice Manifests as Local Muscle Remodelling Without Glycaemic Improvements.

Diabetes, obesity & metabolism·2026
Same journal

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study.

Diabetes, obesity & metabolism·2026
Same journal

Efficacy and Safety of the Dual Glucagon-Like Peptide-1 and Glucagon Receptor Agonist Mazdutide in Predominantly Chinese Adults With Obesity and/or Type 2 Diabetes: A Systematic Review and Meta-Analysis.

Diabetes, obesity & metabolism·2026
Same journal

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice.

Diabetes, obesity & metabolism·2026
Same journal

Efficacy and Safety of Tubeless Hybrid Closed-Loop Systems in Type 1 Diabetes: A Meta-Analysis of Randomized Controlled Trials.

Diabetes, obesity & metabolism·2026
Same journal

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers.

Diabetes, obesity & metabolism·2026
See all related articles

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Disorders

Background:

  • Diabetic individuals face higher cardiovascular disease (CVD) risks and poorer prognoses compared to non-diabetics.
  • Diabetic dyslipidaemia presents as hypertriglyceridaemia, low high-density lipoprotein cholesterol (HDL-C), and small, dense low-density lipoprotein (LDL) particles.

Purpose of the Study:

  • To outline the management strategies for diabetic dyslipidaemia.
  • To define targets and initiation criteria for lipid-lowering therapy in diabetic patients.

Main Methods:

  • Lifestyle modifications including increased physical activity and weight loss.
  • Pharmacological interventions such as cholesterol-lowering drugs, oral hypoglycaemic agents, and insulin therapy.
  • Monitoring of glycemic control and lipid levels (LDL-C, non-HDL-C, triglycerides).

Related Experiment Videos

Main Results:

  • Lifestyle changes and improved glycemic control are primary management steps.
  • Lipid-lowering therapy is indicated if LDL-C remains above 100 mg/dl or triglycerides are >=150 mg/dl despite lifestyle and glycemic control efforts.
  • Intensive insulin therapy can achieve tight glycemic control and reduce triglyceride levels.

Conclusions:

  • Effective management of diabetic dyslipidaemia requires a multi-faceted approach.
  • Achieving target lipid levels is crucial for reducing CVD risk in diabetic patients.
  • Glycemic control is a priority and directly impacts lipid profiles, particularly triglycerides.